Heart attack drug shows promise in reducing inflammation
NCT ID NCT04082442
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding evolocumab, a drug that lowers bad cholesterol, to standard care helps people who recently had a heart attack. The goal was to see if it reduces cholesterol and inflammation in the heart and blood vessels. 100 adults aged 25 to 90 who had a specific type of heart attack took part. The drug is already approved for some patients, but this study looked at its effects right after a heart attack.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which strategy wins for heart attack patients with multiple blocked arteries?
- Can a Plant-Based diet calm the immune system after a heart attack?
- Ultrasound 'Memory' imaging may reveal hidden heart ischemia
- Could a heart MRI replace invasive scans for some heart attacks?
- Can a tailored Blood-Thinner combo prevent second heart attacks without causing bleeding?
- Can a quick shot stop a heart attack in its tracks?